BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 38691909)

  • 1. Insights into the Overcoming EGFR
    Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
    ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
    Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA
    Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
    Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
    Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eco-friendly green synthesis of N‑pyrazole amino chitosan using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR.
    Zhang L; Li C
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):365-373. PubMed ID: 38564118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.
    Li H; Ke R; Zhou Y; Chang S; Wang J; Su C; Wu P; Yang B; Wang Z; Ding K; Ma D
    Eur J Med Chem; 2024 Jun; 272():116473. PubMed ID: 38718625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Effects of the Novel Pyrazolyl-Urea GeGe-3.
    Williams A; Cooper E; Clark B; Perry L; Ponassi M; Iervasi E; Brullo C; Greenhough A; Ladomery M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations of Antioxidant and Anti-Cancer Activities of 5-Aminopyrazole Derivatives.
    Rapetti F; Spallarossa A; Russo E; Caviglia D; Villa C; Tasso B; Signorello MG; Rosano C; Iervasi E; Ponassi M; Brullo C
    Molecules; 2024 May; 29(10):. PubMed ID: 38792163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
    Fadaly WAA; Nemr MTM; Kahk NM
    Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
    Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
    Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR
    El-Gaby MSA; Abdel Reheim MAM; Akrim ZSM; Naguib BH; Saleh NM; El-Adasy ABAAM; El-Adl K; Mohamady S
    Drug Dev Res; 2024 Feb; 85(1):e22143. PubMed ID: 38349267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis,
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.